What could new and emerging options mean for the future of CLL therapy? Patient advocate Jeff Folloder interviews Dr. John Burke, a CLL expert from Rocky Mountain Cancer Centers to learn Dr. Burke’s perspective on developing research. Dr. Burke discusses current options, potential combination approaches and novel second-generation inhibitors.
This program was made possible by Pharmacyclics LLC and Janssen Biotech, Inc. Produced in partnership with Rocky Mountain Cancer Centers.